Introduction
============

As a result of worldwide trends in aging populations, increasing air pollution, smoking rates, environmental carcinogens and a genetic predisposition, lung cancer has become the most common malignancy worldwide, affecting around 13% of all cancer cases globally [@B1]. In 2012, worldwide age-standardized mortality rates for males and females with lung cancer were 30.0/100,000 and 11.1/100,000, respectively, reflecting poor 5-year relative survival rates [@B2]. In 2014, a total of 782,000 new lung cancer cases and 626,000 new lung cancer deaths were documented in China [@B3]. The specific genetic risks underlying lung cancer development and progression are still unclear. Genetic variants and epigenetic changes have been documented to influence the development and progression of non-small cell lung cancer [@B4]. Thus, specific information about genetic aberrations could potentially assist with risk prediction and earlier diagnosis of lung cancer in individual patients.

Angiopoietin-2 (Ang2) is a 75-kDa protein expressed in endothelium that is localized to human chromosomes 8p23.1 and first defined at sites of vascular remodeling [@B5]. Ang2 acts as an autocrine factor in supporting endothelial cell homeostasis and counteracts Ang1 to sensitize endothelium [@B6]. Genetic factors and single nucleotide polymorphisms (SNPs) genotyping are both pivotal to explore the risk and prognosis of tumorigenesis [@B7]-[@B9]. SNPs in the Ang2 intron are known to be associated with breast cancer, lung injury, or acute respiratory distress syndrome [@B10]-[@B12]. A recent study reported an association between the *Ang2* variants, rs2442598, and the risk of psoriasis vulgaris [@B13]. These studies suggest that it is worth exploring a possible correlation between *Ang2* gene polymorphisms and lung cancer diagnosis. Our case-control study therefore explored possible associations between five SNPs in the *Ang2* gene and lung cancer.

Materials and Methods
=====================

Patients and blood samples
--------------------------

We collected blood specimens from 695 patients (cases) diagnosed with lung cancer at Dongyang People\'s Hospital between 2014 and 2018. Nine hundred healthy participants without any history of cancer served as controls. All participants provided written informed consent. The study was approved by the Ethics Committee of Dongyang People\'s Hospital Ethics Committee and Institutional Review Board (2016-YB003). Medical records were reviewed for the clinicopathological characteristics. A standardized questionnaire and electronic medical records were used to acquire detailed clinical data on age, sex, smoking history and alcohol consumption. The pathological stages of lung cancer in all patients were determined by their medical records and the Revised International System for Staging Lung Cancer. Whole blood samples (3 mL) were collected from all study participants and stored at -80°C for subsequent DNA extraction.

Selection of *Ang-2* polymorphisms
----------------------------------

Five *Ang-2* SNPs (rs2442598, rs734701, rs1823375, 11137037, and rs12674822) were selected from the intron of *Ang-2*; all SNPs had minor allele frequencies of greater than 5%. Most *Ang-2* SNPs were known to be associated with lung injury or breast cancer [@B11], [@B14]. The sequence of five Ang2 SNP probes were described as follows: rs2442598, TATGTGTGCGAGGACAGTGTGTGTT\[A/T\]ATTTTGTCCTCTTCTTGATGGTTGA; rs734701, TGTGATATTGTGGAAAGACCTGGTA\[T/C\]TCAAGTAATTTGTTATTCTATTCTC; rs1823375, GTGACTTCTCTTAGGGAGCACACTT\[C/G\]CCTTCACCTGCCCTGACCACATGGA; rs11137037, CCCACCATCCCCCATTGCATGCCCT\[A/C\]AGCAAAGATACTCGTTTTGTGTTTC; rs12674822, GCAATCACTTGTCTGGCCCAACCCT\[G/T\]TATATTATTTGAGGCCCAGAAAAGG.

Genomic DNA extraction and genotyping by real-time PCR
------------------------------------------------------

Total genomic DNA was extracted from peripheral blood leukocytes using a QIAamp DNA blood mini kit (Qiagen, CA, USA), according to the manufacturer\'s instructions [@B15]. Extracted DNA was stored at -20°C and prepared for genotyping by polymerase chain reaction (PCR). DNA was dissolved in TE buffer (10 mM Tris pH 7.8, 1 mM EDTA) and stored at -20°C until quantitative PCR analysis. Five *Ang-2* SNP probes were purchased from Thermo Fisher Scientific Inc. (USA), and allelic discrimination analysis of *Ang-2* SNPs was assessed using a QuantStudio™ 5 Real-Time PCR system (Applied Biosystems, CA, USA), according to the manufacturer\'s instructions. Data were further analyzed with QuantStudio™ Design & Analysis Software (Applied Biosystems) [@B16]. Genotyping PCR was carried out in a total volume of 10 μL containing 20-70 ng genomic DNA, 1 U Taqman Genotyping Master Mix (Applied Biosystems) and 0.25 μL probes. The protocol included an initial denaturation step at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min.

Cell culture
------------

The human lung cancer cell line A549 was purchased from Jennio Biotech Co., Ltd. (Guangzhou, China). F12, fetal bovine serum (FBS) and all other cell culture reagents were purchased from Thermo Fisher Scientific (MA, USA). A549 cells were cultured in F12 supplemented with 10% FBS (Invitrogen, USA) and antibiotics (100 U/mL penicillin and 100 mg/mL streptomycin). Cultures were maintained in a humidified atmosphere of 5% CO~2~ at 37°C as previous description [@B17]. We changed the culture medium twice a week and passaged the cells when they reached 80% confluence.

Western blot analysis
---------------------

We used 11 lung cancer tissues to lyse and resolve through sodium dodecyl sulfate-polyacrylamide gel electrophoresis [@B18]. The target protein was immunoblotted to Immobilon polyvinyl difluoride membranes (Millipore, Billerica, MA, USA). The blots were blocked with 4% non-fat milk for 1 h at room temperature and then probed with rabbit anti-human antibodies against β-actin, and with mouse anti-human antibodies against Ang2 (\#ab155106, Abcam, CA, USA) for 1 h at room temperature. After 3 washes, the blots were incubated with goat anti-rabbit or goat anti-mouse peroxidase-conjugated secondary antibody for 1 h at room temperature. The blots with horseradish peroxidase-labeled substrate were analyzed using a Molecular Imager ChemiDocTM XRS+ chemiluminescence detection system (Bio-Rad, California, USA).

Enzyme-linked immunosorbent assay
---------------------------------

527 serum from the lung cancer patients and healthy controls was measured using an Ang2 ELISA kit, according to the manufacturer\'s instructions [@B19]. The kit was purchased from R&D Systems.

Statistical analysis
--------------------

Differences between the two groups were considered significant if *p* values were less than 0.05. Hardy-Weinberg equilibrium (HWE) was assessed using Chi-square goodness-of-fit tests for bi-allelic markers. Since the data was independent and normal distribution, Fisher\'s exact test was used to compare differences in demographic characteristics between healthy controls and patients with lung cancer. Odds ratios (ORs) combined with 95% confidence intervals (CIs) calculated associations between genotype frequencies and the risk of lung cancer. To further exclude the impact of confounding variables, adjusted odds ratios (AORs) with 95% CIs were estimated by multiple logistic regression models that controlled for age.

A Cox proportional hazard model was used to evaluate the effects of Ang2 genotyping results on the probability of recurrence or overall survival after adjusting for age in multivariate analysis relative to recurrence or survival time. When the follow-up period was included in survival or recurrence analysis, the patients were enrolled for overall survival analysis including the 5-year survival rate or probability of recurrence between primary surgery and death or recurrence or the end of the study (August, 2018) using the Kaplan-Meier model, as well as multivariate and univariate Cox regression models. All data were analyzed using Statistical Analytic System software (v. 9.1, 2005; SAS Institute, Cary, NC, USA).

Results
=======

In the present study, we enrolled 695 patients with lung cancer and 900 cancer-free healthy participants; all were of Chinese Han ethnicity. Between-group differences in general demographic characteristics are listed in Table [1](#T1){ref-type="table"}. The mean age was 43.35 ± 18.01 years for the lung cancer cohort and 59.72 ± 10.81 years for the controls (*p*\<0.001). There were no between-group differences for gender distribution (*p*=0.891), although significantly higher proportions of lung cancer patients compared with controls were either current or historical cigarette smokers, or consumed alcohol (both *p*\<0.001). According to the American Joint Committee on Cancer (AJCC) tumor/node/metastasis (TNM) classification and staging system, we identified 512 patients (73.7%) with clinical stage I and 110 patients (26.3%) with clinical stage II, III, or IV disease. The patients were categorized by type of lung cancer, i.e., non-small cell lung cancer (NSCLC) (97.2%), or small cell lung cancer (SCLC) (2.8%), or by histology, i.e., adenocarcinoma (80.3%), squamous cell carcinoma (14.7%), and other carcinomas (5.0%) (Table [1](#T1){ref-type="table"}).

First, we genotyped the patients with lung cancer (cases) and healthy participants (controls), to evaluate whether the five *Ang2* SNPs (rs2442598, rs734701, rs1823375, 11137037, and rs12674822) were associated with the risk of lung cancer. The results are illustrated in Table [2](#T2){ref-type="table"}. Alleles with the highest distribution frequency at *Ang2* rs2442598, rs734701, rs1823375, 11137037, and rs12674822 in both cases and controls were heterozygous AT, heterozygous TC, homozygous CC, homozygous AA, and heterozygous GT, respectively (Table [2](#T2){ref-type="table"}). Individuals carrying the GT heterozygote at rs12674822 had a 1.281-fold (95% CI: 1.016-1.617, *p*\<0.05) higher risk of lung cancer compared with individuals carrying the wild-type GG polymorphic allele. Individuals with polymorphisms at rs2442598, rs734701, rs1823375, and rs11137037 showed no significant associations with lung cancer risk relative to the risk in individuals with the wild-type genotype (Table [2](#T2){ref-type="table"}).

Next, *Ang2* genotypes in patients with lung cancer were evaluated to clarify the role of *Ang2* polymorphisms in TNM stage, primary tumor size, lymph node metastasis, and distant metastasis. For 475 patients with lung cancer, a significant correlation between rs11137037 variants (GG vs AG) and clinical stage (OR: 1.584, 95% CI: 1.021-2.456, *p*\<0.05) was observed (Table [3](#T3){ref-type="table"}). However, no significant differences were observed between *Ang2* rs12674822 genotypes and clinicopathological status (the data are not shown). Distribution frequencies for clinical status in the NSCLC and SCLC cohorts are shown in Table [4](#T4){ref-type="table"}. Most of the patients were in the NSCLC category. Significant correlations were observed between types of lung cancer (NSCLC vs SCLC) and clinical stage (OR: 29.543, 95% CI: 6.809-128.181, *p*\<0.001), tumor size (OR: 22.515, 95% CI: 5.196-97.568, *p* = 0.001), lymph node metastasis (OR: 42.137, 95% CI: 9.688-183.263, *p*\<0.001) and distant metastasis (OR: 11.054, 95% CI: 4.513-27.077, *p*\<0.001), respectively (Table [4](#T4){ref-type="table"}). For 527 patients with NSCLC, a significant correlation was observed between rs12674822 variants (GG vs GT) and clinical stage (OR: 1.555, 95% CI: 1.011-2.391, *p*\<0.05; AOR: 1.589, 95% CI: 1.029-2.455, *p*\<0.05, respectively) (Table [5](#T5){ref-type="table"}). However, there were no significant differences observed between histology subgroups and polymorphisms of the *Ang2* genotypes (the data are not shown).

We measured Ang2 protein expression in primary tissues and blood samples from our patients as well as lung cancer cell line, A549 (Fig. [1](#F1){ref-type="fig"}A and B). We used the Kaplan-Meier survival curve to analyze correlations of *Ang2* polymorphisms with overall survival and progression-free survival (supplementary Fig. [S1](#SM0){ref-type="supplementary-material"}). Cox proportional hazards analysis revealed that patients carrying AC+CC at rs11137037 had longer five-year overall survival (*p*=0.049; hazard ratio: 0.645, 95% CI: 0.417-0.998), while those carrying GT+TT at rs12674822 had longer progression-free survival (*p*=0.027; hazard ratio: 0.437, 95% CI: 0.213-0.896), compared with those carrying wild-type variants (the data are not shown).

Discussion
==========

It is recognized that several SNP genes affect an individual\'s susceptibility to lung cancer [@B20]-[@B22]. Correlations between *Ang2* gene polymorphisms and lung cancer have rarely been documented and most of the evidence is associated with lung injury syndromes [@B11], [@B23]. It is essential that we know more about genetic polymorphisms, in order to help us to explore novel therapeutic strategies for lung cancer [@B24], [@B25]. To the best of our knowledge, our study provides the first clinical evidence on associations between *Ang2* polymorphisms (rs2442598, rs734701, rs1823375, 11137037, and rs12674822) and lung cancer susceptibility, as well as on interactions between these polymorphisms and clinical characteristics in a Chinese Han population. In this study, we increased our overall numbers of participants by incorporating the patients and controls included in our previous study [@B25]. Our results show that *Ang2* gene polymorphisms only slightly increased the susceptibility for lung cancer. This might be because most of our study participants were nonsmokers (i.e., controls and patients), and because the ratios of cigarette smokers/nonsmokers among the controls (11.1:88.9) and patients (35.8:64.2) were relatively normal, as were the proportions of those who consumed alcohol. Although our results demonstrated that smoking and alcohol consumption were significant risk factors for lung cancer (Table [1](#T1){ref-type="table"}; both *p*\<0.001), the significance of this association did not persist in *Ang2* SNPs genotyping analyses that controlled for smoking and alcohol consumption (these data are not shown).

*Ang2* involvement has been observed in lung cancer metastasis [@B26], [@B27]. Further investigations have revealed that *Ang2* is not only pro-angiogenic but also pro-inflammatory factors in cancer development [@B28], [@B29]. We therefore sought to determine if our data could emulate this finding. We initially measured *Ang2* expression in lung cancer tissue and serum samples, but the low number of lung cancer samples meant that we could not analyze the immunostaining results for *Ang2*. Moreover, although the 5-year survival rates among our patients were significantly associated with clinical status (these data are not shown), this significant association disappeared in an *Ang2* SNP genotyping analysis (Fig. [S1](#SM0){ref-type="supplementary-material"}). Owing to this unusual protective survival correlation between Ang2 polymorphism rs11137037 and clinical stage, it might be associated with early clinical stage and well survive of these lung cancer patients. In a previous study, two *Ang2* SNPs (rs1868554 and rs2442598) were significantly associated with acute lung injury [@B11]. However, our results are the first to demonstrate that *Ang2* gene polymorphisms at rs12674822 but not at rs2442598 are significantly related to the risk of developing lung cancer. We also found that patients with the CC genotype at rs11137037 were 1.58 times more likely to develop stage II, III or IV disease. The correlation between Ang2 polymorphism and the lung cancer cells required to be further discussed in the future.

Although blockade of the programmed death-1 receptor ligand 1 pathway is a powerful therapeutic strategy for NSCLC [@B30], this disease still has a dismal prognosis [@B31], [@B32], so genetic information that can be useful for lung cancer prognosis or prediction is essential. Our results reveal a significant correlation between NSCLC and clinical status in 695 Chinese Han patients; in 527 patients with NSCLC, those with *Ang2* polymorphisms carrying the GT genotype at rs12674822 were 1.56-fold more likely to develop stage II, III or IV disease. Others Ang2 polymorphisms were not associated with a certain type of lung cancer since the populations were too small to analyze. On the other hand, a reconstructed linkage disequilibrium plot of the five *Ang2* SNPs failed to reveal any significant difference between the clinical stages of the disease (supplementary Fig. [S2](#SM0){ref-type="supplementary-material"}).

In summary, our results demonstrate an association between one *Ang2* gene variant and risk of lung cancer, with a significant association between *Ang2* SNP rs12674822 and stage II, III, or IV disease in a Chinese Han population. This study is the first to report any such correlation between *Ang2* polymorphisms and risk of lung cancer. Our evidence indicates that *Ang2* could be developed as a genetic prognostic marker for lung cancer prognosis.

Supplementary Material {#SM0}
======================
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Supplementary figures.
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Click here for additional data file.
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![**High expression of *Ang2* in lung cancer tissue and serum samples.** (A) Human lung cancer and normal lung tissue samples and lung cancer cell line A549 were used to purify proteins, and *Ang2* expression was measured by Western blot. (B) Blood serum samples were collected from patients and controls and analyzed by enzyme-linked immunosorbent assay (ELISA). The results are expressed as the mean ± standard error of the mean (S.E.M.) of three separate experiments.](jcav10p2935g001){#F1}

###### 

Demographic and clinical characteristics of healthy cancer-free controls and patients with lung cancer.

  Variable                                      Controls (N=900)   Patients (N=695)   *p* value
  --------------------------------------------- ------------------ ------------------ ------------
  **Age (yrs)**                                 **Mean ± S.D.**    **Mean ± S.D.**    
                                                43.35 ± 18.01      59.72 ± 10.81      *p*\<0.001
  **Gender**                                    **N (%)**          **N (%)**          
  Female                                        470 (52.2)         358 (51.5)         
  Male                                          430 (47.8)         337 (48.5)         *p*=0.891
  **Historical or current cigarette smokers**                                         
  No                                            800 (88.9)         446 (64.2)         
  Yes                                           100 (11.1)         249 (35.8)         *p*\<0.001
  **Alcohol consumption**                                                             
  No                                            783 (87.0)         472 (67.9)         
  Yes                                           117 (13.0)         223 (32.1)         *p*\<0.001
  **Clinical stage**                                                                  
  I                                                                512 (73.7)         
  II, III, IV                                                      183 (26.3)         
  **Tumor size**                                                                      
  \<T2                                                             476 (68.5)         
  ≧T2                                                              219 (31.5)         
  **Lymph node status**                                                               
  N0                                                               552 (79.4)         
  N1, N2, N3                                                       143 (20.6)         
  **Metastasis**                                                                      
  M0                                                               623 (89.6)         
  M1                                                               72 (10.4)          
  **Types of lung cancer**                                                            
  NSCLC                                                            674 (97.2)         
  SCLC                                                             21 (2.8)           
  **Histology**                                                                       
  Adenocarcinoma                                                   541 (77.8)         
  Squamous cell carcinoma                                          99 (14.2)          
  Other carcinoma                                                  55 (7.9)           

The Fisher\'s exact test was used to compare independent data between controls and patients with lung cancer. \* *p* value \<0.05 was considered statistically significant. NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.

###### 

Distribution frequencies of *Ang2* genotypes in healthy cancer-free controls and patients with lung cancer.

  ------------------------------------------------------------------------------
  Variable         Controls\    Patients\    OR (95% CI)             *p* value
                   N=900 (%)    N=695 (%)                            
  ---------------- ------------ ------------ ----------------------- -----------
  **rs2442598**                                                      

  AA               252 (28.0)   188 (27.1)   1.00 (reference)        

  AT               464 (51.6)   337 (48.5)   0.974 (0.769-1.232)     *p*=0.823

  TT               184 (20.4)   170 (24.5)   1.238 (0.935-1.641)     *p*=0.136

  AT+TT            648 (72.0)   507 (73.0)   1.049 (0.840-1.309)     *p*=0.674

  **rs734701**                                                       

  TT               305 (33.9)   226 (32.5)   1.00 (reference)        

  TC               403 (44.8)   351 (50.5)   1.175 (0.940-1.470)     *p*=0.157

  CC               192 (21.3)   118 (17.0)   0.829 (0.623-1.105)     *p*=0.201

  TC+CC            595 (66.1)   469 (67.5)   1.064 (0.862-1.313)     *p*=0.565

  **rs1823375**                                                      

  CC               451 (50.1)   342 (49.3)   1.00 (reference)        

  CG               372 (41.3)   282 (40.6)   1.000 (0.811-1.232)     *p*=0.998

  GG               77 (8.6)     71 (10.2)    1.216 (0.855-1.729)     *p*=0.276

  CG+GG            449 (49.9)   353 (50.8)   1.037 (0.851-1.264)     *p*=0.721

  **rs11137037**                                                     

  AA               417 (46.3)   344 (49.5)   1.00 (reference)        

  AC               331 (36.8)   221 (31.8)   0.809 (0.648-1.011)     *p*=0.062

  CC               152 (16.9)   130 (18.7)   1.037 (0.788-1.364)     *p*=0.796

  AC+CC            483 (53.7)   351 (50.5)   0.881 (0.723-1.074)     *p*=0.210

  **rs12674822**                                                     

  GG               283 (31.4)   191 (27.5)   1.00 (reference)        

  GT               407 (45.2)   352 (50.6)   1.281 (1.016-1.617)\*   *p*=0.036

  TT               210 (23.3)   152 (21.9)   1.072 (0.812-1.416)     *p*=0.622

  GT+TT            617 (68.6)   504 (72.5)   1.210 (0.973-1.505)     *p*=0.086
  ------------------------------------------------------------------------------

Odds ratios and their confidence intervals were estimated by logistic regression models. \* *p* value \<0.05 was considered statistically significant. OR, odds ratio; CI, confidence interval; Ang2, angiopoietin-2.

###### 

Odds ratios and their confidence intervals for the clinical status and *Ang2* rs11137037 genotypic frequencies of 474 lung cancer patients.

  ---------------------------------------------------------------------------------------------
  Variable                    AA\          CC\          OR (95% CI)                 *p* value
                              N=344 (%)    N=130 (%)                                
  --------------------------- ------------ ------------ --------------------------- -----------
  **Clinical Stage**                                                                

  Stage I                     260 (75.6)   86 (66.2)    1.00                        

  Stage II/III/IV             84 (24.4)    44 (33.8)    **1.584 (1.021-2.456)\***   *p*=0.039

  **Tumor size**                                                                    

  \<T2                        239 (69.5)   79 (60.8)    1.00                        

  ≧T2                         105 (30.5)   51 (39.2)    1.469 (0.965-2.237)         *p*=0.072

  **Lymph node metastasis**                                                         

  No                          279 (81.1)   95 (67.9)    1.00                        

  Yes                         65 (18.9)    35 (32.1)    1.581 (0.986-2.536)         *p*=0.056

  **Distant metastasis**                                                            

  No                          310 (90.1)   112 (86.2)   1.00                        

  Yes                         34 (9.9)     18 (13.8)    1.465 (0.796-2.699)         *p*=0.218
  ---------------------------------------------------------------------------------------------

Odds ratios with their confidence intervals were estimated by logistic regression models. \* *p* value \<0.05 was considered statistically significant. OR, odds ratio; CI, confidence interval; Ang2, angiopoietin-2.

###### 

Clinical details of patients with NSCLC or SCLC.

  ------------------------------------------------------------------------------------------------
  Variable                    NSCLC\       SCLC\       OR (95% CI)                    *p* value
                              N=674 (%)    N=21 (%)                                   
  --------------------------- ------------ ----------- ------------------------------ ------------
  **Clinical Stage**                                                                  

  Stage I                     510 (75.7)   2 (9.5)     1.00                           

  Stage II/III/IV             164 (24.3)   19 (90.5)   **29.543 (6.809-128.181)\***   *p*\<0.001

  **Tumor size**                                                                      

  \<T2                        474 (70.3)   2 (9.5)     1.00                           

  ≧T2                         200 (29.7)   19 (90.5)   **22.515 (5.196-97.568)\***    *p*=0.001

  **Lymph node metastasis**                                                           

  No                          550 (81.6)   2 (9.5)     1.00                           

  Yes                         124 (18.4)   19 (90.5)   **42.137 (9.688-183.263)\***   *p*\<0.001

  **Distant metastasis**                                                              

  No                          613 (90.9)   10 (47.6)   1.00                           

  Yes                         61 (9.1)     11 (52.4)   **11.054 (4.513-27.077)\***    *p*\<0.001
  ------------------------------------------------------------------------------------------------

Odds ratios with their confidence intervals were estimated by logistic regression models.

\* *p* value \<0.05 as statistically significant. OR, odds ratio; CI, confidence interval; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.

###### 

Associations of *Ang2* rs12674822 genotypic frequencies with laboratory status in the NSCLC cohort.

  -------------------------------------------------------------------------------------------------------------
  Variable                    GG\          GT\          OR (95% CI)                 AOR (95% CI)
                              N=182 (%)    N=345 (%)                                
  --------------------------- ------------ ------------ --------------------------- ---------------------------
  **Clinical Stage**                                                                

  Stage I                     145 (79.7)   247 (71.6)   1.00                        1.00

  Stage II/III/IV             37 (21.8)    98 (28.4)    **1.555 (1.011-2.391)\***   **1.589 (1.029-2.455)\***

  **Tumor size**                                                                    

  \<T2                        133 (73.1)   233 (67.5)   1.00                        1.00

  ≧T2                         49 (26.9)    112 (32.5)   1.305 (0.877-1.942)         1.332 (0.890-1.994)

  **Lymph node metastasis**                                                         

  No                          154 (84.6)   269 (78.0)   1.00                        1.00

  Yes                         28 (15.4)    76 (22.0)    1.554 (0.965-2.502)         1.583 (0.980-2.559)

  **Distant metastasis**                                                            

  No                          166 (91.2)   312 (90.4)   1.00                        1.00

  Yes                         16 (8.8)     33 (9.6)     1.097 (0.587-2.052)         1.111 (0.592-2.083)
  -------------------------------------------------------------------------------------------------------------

Odds ratios with their confidence intervals were estimated by logistic regression models. Ang2, angiopoietin-2; NSCLC, non-small cell lung cancer; OR, odds ratio; CI, confidence interval; AOR, adjusted odds ratio. \* *p* value \<0.05 as statistically significant.
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